Advertisement
Screener

Aura Biosciences, Inc. (AURA) Proceeds from (Payments for) Other Financing Activities

2.8 / 5 stars · 68/120 Roast Me

Aura Biosciences, Inc. Proceeds from (Payments for) Other Financing Activities

Aura Biosciences, Inc. (AURA) reported Proceeds from (Payments for) Other Financing Activities of -$15.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-15.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2023-03-15

  • Aura Biosciences, Inc. proceeds from (payments for) other financing activities for the quarter ending 2021-03-31 was -$9.00K.
  • Aura Biosciences, Inc. proceeds from (payments for) other financing activities for the quarter ending 2020-12-31 was -$9.00K.
  • Aura Biosciences, Inc. proceeds from (payments for) other financing activities for fiscal 2021 was -$15.00K.
  • Aura Biosciences, Inc. proceeds from (payments for) other financing activities for fiscal 2020 was -$34.00K.
Period endProceeds from (Payments for) Other Financing Activities 3 monthProceeds from (Payments for) Other Financing Activities 6 monthProceeds from (Payments for) Other Financing Activities 9 monthProceeds from (Payments for) Other Financing Activities 12 month
2021-12-31-$15.00K
10-K · filed 2023-03-15
2021-03-31-$9.00K
10-Q · filed 2022-05-12
-$18.00K
derived: sum of 2 quarters · filed 2022-05-12
2020-12-31-$9.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
-$34.00K
10-K · filed 2022-03-23
2020-09-30-$25.00K
10-Q · filed 2021-11-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Allogene Therapeutics, Inc. (ALLO)United States$0.574B-4.33
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Entera Bio Ltd. (ENTX)$0.485B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B